A clinical research of magnesium isoglycyrrhizinate trerapy for liver lesion in transcatheter arterial chemoembolization

Objective To explore the clinic effect of Magnesium isoglycyrrhizinate on the patients with primary hepatic carcinoma after transcatheter arterial chemoembolization(TACE).Methods 105 cases with malignant tumor complicated with liver lesion induced by TACE were randomly divided to receive magnesium isoglycyrrhizinate therapy(treatment group) or diammonium glycyrrhizinate injection(control group) with 150 mg iv gtt qd from Preoperative 3 days to the 7th day after TACE operation.The incidences of the adverse effect after TACE operation were memorized.Results The levels of TBIL,ALT and AST on the 2nd day after TACE operation were higher than those before TACE operation in the two groups(P0.05).The levels of ALT and AST on the 7th day after TACE operation were revivaled in the therapy group(P0.05). But the levels of ALT and AST in the control group on the 7th day were higher than those before TACE operation(P0.05).The index of the synthesis ability of hepatocyte was not improved in the therapy group(P0.05).The incidence of the adverse effect in the therapy group was lower than that in the control group(P0.05).Conclusion Magnesium isoglycurrhizinate can distinctly protect the liver function of the patients with primary hepatic carcinoma after TACE operation and prevent the adverse effect.